Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 2: Integration of PARP Inhibitor Maintenance Therapy into the Management of Newly Diagnosed OC — Dr Moore CME information and select publications

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 3: Potential Role of PARP Inhibitors with Chemotherapy; Other Investigational Combination Approaches in Clinical Development for Advanced OC — Dr Coleman CME information and select publications

Beyond the Guidelines: Perspectives on the Role of PARP Inhibition in the Management of Ovarian Cancer — Faculty Presentation 4: Practical Considerations with the Use of PARP Inhibitors in Advanced OC — Dr Lheureux CME information and select publications

Proceedings from an independent satellite symposium during the Society of Gynecologic Oncology’s 2020 Annual Meeting on Women’s Cancer Webinar Series. Featuring perspectives from Drs Robert L Coleman, Stephanie Lheureux, Joyce F Liu and Kathleen Moore.

• Considerations for the use of a PARP inhibitor as a component of up-front treatment for patients with ovarian cancer (OC) (00:00)
• Selection of mutation assay for patients with newly diagnosed OC (5:27)
• PARP inhibitor maintenance therapy for newly diagnosed OC; recently FDA-approved options (13:55)
• Integration of PARP inhibitor monotherapy or combination with bevacizumab into maintenance therapy for newly diagnosed OC (24:47)
• Can homologous recombination deficiency testing guide therapeutic decision-making for patients with OC? (34:20)
• Treatment approach for patients who experience disease progression on a PARP inhibitor; potential role of switching to another PARP inhibitor (40:04)
• Clinical care of patients who receive a PARP inhibitor and experience side effects or other tolerability issues requiring dose adjustment or discontinuation (44:24)
• “Manage Wisely: PARP inhibitor treatment and adverse events” (53:17)
• Design, efficacy and safety findings from the Phase III VELIA trial evaluating veliparib in combination with carboplatin and paclitaxel and as continuation maintenance therapy for newly diagnosed advanced OC; implications for clinical practice (58:47)
• Choice of PARP inhibitor for patients with platinum-sensitive OC (1:08:08)
• ASCO 2020 Abstract 6002: Final overall survival results from SOLO2/ENGOT-ov21: A Phase III trial assessing maintenance olaparib in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (1:15:06)

CME information and select publications

Proceedings from a CME webinar focused on COVID-19 and chronic lymphocytic leukemia. Featuring perspectives from Drs Matthew S Davids, Anthony R Mato and Jeff Sharman.

• Changes in chronic lymphocytic leukemia (CLL) institutional processes and procedures brought on by the COVID-19 pandemic (00:00)
• Case: A woman in her late 50s with a history of breast cancer requires treatment for CLL during the pandemic (9:03)
• Recommendations regarding the management of CLL in the COVID-19 environment (14:37)
• Rationale for the use of Bruton tyrosine kinase inhibitors for patients with cancer and COVID-19 (18:29)
• Current approach for patients with CLL requiring treatment with venetoclax/obinutuzumab (20:49)
• Case: A woman in her early 60s with CLL in remission after treatment with an obinutuzumab-based therapy on a clinical trial receives results of a prescribed study-related CT scan that are suspicious for COVID-19 infection (28:16)
• Limitations of COVID-19 testing techniques and platforms (drive-through testing, false-negative rates, et cetera) (34:31)
• Case: A man in his early 70s with relapsed/refractory CLL is hospitalized with COVID-19; potential role of noncancer therapeutic interventions (eg, remdesivir, anticoagulants) (39:44)
• Perspectives on continuing versus stopping therapy both before and during the current pandemic (47:18)
• Case: A man in his early 70s who is receiving PI3 kinase inhibitor therapy for relapsed/refractory CLL begins to experience symptoms of COVID-19 after his wife tests positive for the novel coronavirus (53:03)

CME information and select publications